Exploring Polycystic Kidney Disease Clinical Trials and New Treatments

This webinar explores polycystic kidney disease (PKD) with a focus on autosomal dominant PKD (ADPKD), including clinical presentations, considerations for conducting clinical trials in this population and the future of ADPKD treatment.

In the United States, approximately 600,000 people have PKD¹, making it the fourth leading cause of kidney failure, and there is no cure presently available.²

Men and women are equally at risk for this inherited disorder, and about 90% of PKD cases are ADPKD, meaning only one copy of the abnormal gene, either PKD1 or PKD2, is needed to cause the disease.

Globally, ADPKD affects approximately 12 million people³ and is the most common cause of genetic kidney failure.

The featured speakers highlight the current landscape for ADPKD, factors to consider for clinical trials and what the future may hold for possible new therapies. They will consider the novel challenges and opportunities that these evolving questions present in addressing the urgent need for increasing the number of safe and effective treatments for people living with ADPKD.

Watch this webinar to learn how polycystic kidney disease clinical trials are shaping the future of ADPKD treatment.